Optimising Cardiorenal Outcomes Through Early Initiation of SGLT2 Inhibitors


13:30 – 13:45Achieving Impactful Goals of Care  
13:45 – 14:05Maximising Cardiorenal Protection With SGLT2 Inhibition in Diverse Patient Populations 
14:05 – 14:25SGLT2is in Heart Failure, CKD And T2D – What Does The Evidence Say? 
14:25 – 14:45SGLT2i Benefits on Renal Outcomes – Real World Evidence 
14:45 – 15:00SGLT2is In Clinical Practice